XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 546 participants.
Also called NCT01178268
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 546 participants
- Sponsor
- Registry
-
NCT01178268
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01178268. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2016-08-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
- Condition
- Coronary Occlusion
- Condition
- Thrombosis (Stent Thrombosis)
- Condition
- Vascular Disease
- Condition
- Myocardial Ischemia
- Condition
- Coronary Artery Stenosis
- Condition
- Coronary Disease
- Condition
- Coronary Artery Disease
- Condition
- Coronary Restenosis
- Intervention (Device)
- XIENCE V EECSS
- Intervention (Device)
- CYPHER SELECT PLUS SECSS
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct01178268- Content hash
85135a23669b2b5275f281675ec11bd6ed5b3d6418e7a234ec62d875446bdff5